IDEAYA darovasertib Phase 2 uveal melanoma data: 75% eye saved, 47% median tumor shrinkage

IDEAYA Biosciences, Inc.

Investigator-sponsored Phase 2: 75% of enucleation patients (9/12) had eye saved (converted to brachytherapy/EBRT) after 6 months.
Median tumor shrinkage 47% (max volume change) in 12 enucleation patients; 67% had >30% shrinkage after 6 months.
Company-sponsored Phase 2: 8 patients at ≥4 months showed median tumor volume shrinkage 72%; majority of enucleation patients converted to eye saved.
Drug-related AEs predominantly Grade 1-2; no drug-related serious AEs in either trial.
Data presented at ASCO 2024; trial enrolled over 40 patients across 14+ sites globally.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.